Method of treating malignant tumors with thyroxine analogues...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/235 (2006.01) A61K 31/166 (2006.01) A61K 31/192 (2006.01) C07C 69/92 (2006.01)

Patent

CA 2257235

The present invention provides methods for treating cancer, particularly malignant tumors, with thyroxine analogues having no significant hormonal activity. A thyroxine analogue is administered to an afflicted mammal in an amount effective to cause depression or regression of malignant tumor growth or to treat cancer. Particularly preferred thyroxine analogues are those capable of causing about 35 percent or more inhibition of initial velocity of microtubule protein assembly in vitro.

La présente invention concerne des procédés de traitement du cancer, notamment de tumeurs malignes, avec des analogues de thyroxine n'ayant pas d'activité hormonale importante. Un analogue de thyroxine est administré, à un animal atteint d'une tumeur, dans une quantité efficace afin d'inhiber l'évolution de la tumeur maligne ou de traiter le cancer. Notamment, les analogues de thyroxine préférés sont ceux capable d'inhiber ou faire régresser au moins 35 % de la vitesse initiale de l'ensemble de la protéine microtubulaire in vitro.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Method of treating malignant tumors with thyroxine analogues... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of treating malignant tumors with thyroxine analogues..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating malignant tumors with thyroxine analogues... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-2010804

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.